¹Department of Pharmaceutical science, Faculty of Pharmacy, Petra University, Amman, Jordan
²Albasheer Hospital, Amman, JORDAN
³Triumpharma LLC, Amman, JORDAN DOI : 10.29228/jrp.713 Therapeutic drug monitoring (TDM) is a helpful method to make sure that drugs are prescribed, delivered, and experienced by patients at the intended therapeutic levels. There are several ways to carry out TDM. The TDM of carbamazepine utilizing salivary samples is not, however, supported by enough data. The aim of this study is to evaluate the possibility of utilizing salivary samples in place of plasma samples for the TDM of carbamazepine. In this study, an observational design was used. Where 14 patients in total took part. For comparison, carbamazepine plasma and salivary samples were taken at maximum and minimum levels. Carbamazepine levels were tested using calibrated LC MS-MS then ANOVA test was used for statistical analysis. Obtaining ethical permission came before sample collection. The minimum plasma and salivary levels concentrations were significantly correlated (p = 0.025, r=0.59). Maximum plasma and salivary levels of carbamazepine concentrations were significantly correlated (p = 0.005, r=0.7). AST was significantly correlated with maximum plasma carbamazepine concentrations (p = 0.036, r = 0.8). No other significant relationships were found between carbamazepine concentrations and sociodemographic characteristics. In conclusion, saliva samples can be used as an alternative to plasma samples while monitoring the therapeutic effects of carbamazepine. Compared to plasma TDM for carbamazepine, salivary TDM offers the benefit of being non-invasive and safer than blood sampling. Keywords : Salivary excretion classification system; therapeutic drug monitoring; carbamazepine; pk-sim